B-Cell Lymphomas

Common Name(s)

B-Cell Lymphomas

Lymphoma is the most common blood cancer. Lymphocytes are a type of white blood cell that are part of our body’s immune system and help our body fight infections. Lymphoma occurs when these lymphocytes grow and multiply uncontrollably. The body has two main types of lymphocytes, B-lymphocytes (B-cells) and T-lymphocytes (T-cells). B-cell lymphoma occurs when the B-cells in particular grow into lymphomas. The cancerous lymphocyte cells can then travel to various parts of the body including the lymph nodes, blood, spleen, bone marrow and other organs. There are many different types of B-cell lymphomas and the most common type is called diffuse large b-cell lymphoma (DLBCL) which is aggressive (fast-growing) and requires immediate treatment. There are other forms that are slow-growing and respond well to treatment and can go into remission for many years. Genetic factors as well as environmental factors, weak immune system (immunodeficiency due to an organ transplant or HIV/AIDS), drug and chemical exposures, viruses and other unknown factors are thought to play a role in the development of lymphoma.

Symptoms are variable but can include: swollen lymph glands, fevers, night sweats, fatigue, unexplained weight loss, pain or abdominal bloating, chest pain, cough, difficulty breathing. Diagnosis may include physical exam of the lymph nodes, spleen and liver, blood tests, x-rays, scans, and finally a biopsy from lymph tissue. The treatment and prognosis or outlook depends upon the specific type of B-cell lymphoma and other factors present but often includes radiation, chemotherapy and medications. Speak with your physician for the most current treatment options. Support groups are also a great resource for support and information and can help connect you to other individuals with B-cell lymphoma.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "B-Cell Lymphomas" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "B-Cell Lymphomas" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "B-Cell Lymphomas" returned 538 free, full-text research articles on human participants. First 3 results:

A new diagnostic marker for differentiating multicentric gliomas from multiple intracranial diffuse large B-cell lymphomas on 18F-FDG PET images.
 

Author(s): Kai Wang, Xiaobin Zhao, Qian Chen, Di Fan, Zhen Qiao, Song Lin, Tao Jiang, Jianping Dai, Lin Ai

Journal: Medicine (Baltimore). 2017 Aug;96(32):e7756.

 

Intracranial gliomas and lymphomas may share similar radiological manifestations, while the treatment strategies for them are different. The aim of the study was to investigate the diagnostic value of fluorine-18-fluoro-2-deoxy-D-glucose (F-FDG) positron emission computed tomography ...

Last Updated: 10 Aug 2017

Go To URL
Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.
 

Author(s): Nara Yoon, Soomin Ahn, Hae Yong Yoo, Suk Jin Kim, Won Seog Kim, Young Hyeh Ko

Journal: Oncotarget. 2017 Mar;8(13):22014-22022.

 

Diffuse large B-cell lymphomas (DLBCLs) are clinically heterogeneous and need a biomarker that can predict the outcome of treatments accurately. To assess the prognostic significance of the cell-of-origin type for DLBCLs, we applied the Lymph2Cx assay using a NanoString gene expression ...

Last Updated: 20 Apr 2017

Go To URL
Next-generation sequencing of miRNAs in clinical samples of Epstein-Barr virus-associated B-cell lymphomas.
 

Author(s): Kouta Sakamoto, Tsuyoshi Sekizuka, Taeko Uehara, Tsunekazu Hishima, Sohtaro Mine, Hitomi Fukumoto, Yuko Sato, Hideki Hasegawa, Makoto Kuroda, Harutaka Katano

Journal: Cancer Med. 2017 Mar;6(3):605-618.

 

Epstein-Barr virus (EBV) encodes 49 microRNAs (miRNAs) in the BART and BHRF1 regions of its genome. Although expression profiles of EBV-encoded miRNAs have been reported for EBV-positive cell lines and nasopharyngeal carcinoma, to date there is little information about total miRNA ...

Last Updated: 9 Feb 2017

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "B-Cell Lymphomas" returned 44 free, full-text review articles on human participants. First 3 results:

Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?
 

Author(s): Fabienne McClanahan, Thomas G Sharp, John G Gribben

Journal: Haematologica. 2016 Oct;101(10):1144-1158.

 

Therapeutic strategies targeting the programmed cell death-ligand 1/programmed cell death-1 pathway have shown significant responses and good tolerability in solid malignancies. Although preclinical studies suggest that inhibiting programmed cell death-ligand 1/programmed cell death-1 ...

Last Updated: 3 Oct 2016

Go To URL
Cutaneous B-cell lymphomas: 2016 update on diagnosis, risk-stratification, and management.
 

Author(s): Ryan A Wilcox

Journal: Am. J. Hematol.. 2016 Oct;91(10):1052-5.

 

Approximately one-fourth of cutaneous lymphomas are B-cell derived and are generally classified into three distinct subgroups: primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL), and primary cutaneous diffuse large B-cell lymphoma, ...

Last Updated: 21 Sep 2016

Go To URL
Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides.
 

Author(s): Meenal Kheterpal, Neha Mehta-Shah, Pooja Virmani, Patricia L Myskowski, Alison Moskowitz, Steven M Horwitz

Journal: Curr Hematol Malig Rep. 2016 Jun;11(3):224-33.

 

Cutaneous lymphomas (CL) are a heterogeneous group of neoplasms characterized with clinical and histopathological variation, as well as overlap with benign dermatoses. Diagnosis and treatment of CLs is challenging and often requires a multidisciplinary approach. However, prognostic ...

Last Updated: 5 May 2016

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas
 

Status: Recruiting

Condition Summary: B-cell Lymphoma

 

Last Updated: 8 Mar 2017

Go to URL
A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas
 

Status: Recruiting

Condition Summary: B-Cell Lymphoma

 

Last Updated: 22 Nov 2016

Go to URL
A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)
 

Status: Not yet recruiting

Condition Summary: B-cell Lymphoma

 

Last Updated: 16 Oct 2017

Go to URL